Big Pharma: 2012-13′s Flu Vaccine Field

A look at the players that could see a bump this flu season

Dec 13, 2012, 9:14 am EDT | By James Brumley, InvestorPlace Contributor

Sanofi

Sanofi SA (SNY) French pharmaceutical company Sanofi (NYSE:SNY) said in the middle of the year that it plans to ship 60 million doses of its seasonal flu vaccine this year. Those shipments largely consist of Fluzone in a handful of doses and target patient profiles.

Sanofi also makes several other influenza vaccines, including Intanza (IDflu), Panenza, Humenza and Vaxigrip (Mutagrip), though you should note that not all of those are used in the United States.

Either way, Fluzone is the company’s flagship drug in the category, with 2012’s likely global revenue approaching $1.343 billion.